Resource impact statement
No significant resource impact is anticipated
NICE has recommended ponesimod as an option for treating relapsing–remitting multiple sclerosis with active disease defined by clinical or imaging features in adults, only if the company provides ponesimod according to the commercial arrangement.
This recommendation is not intended to affect treatment with ponesimod that was started in the NHS before the guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before the guidance was published, until they and their NHS clinician consider it appropriate to stop.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population).
This is because the technology is a further treatment option and the overall cost of treatment will be similar.
The use of ponesimod is not expected to result in additional service requirements. It is a further oral treatment option which can increase convenience for people who use it and may save costs. The use of ponesimod may also free up healthcare professional capacity compared to treatments administered by intravenous infusions in hospital. However, any savings as a result are not expected to be significant at a national level.
Ponesimod has a discount that is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: